Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India and internationally. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialty drugs, and active pharmaceutical ingredients (APIs). The company offers formulations for use in the therapeutic areas of anti-tuberculosis, diabetes management, cardiovascular, chronic obstructive pulmonary diseases, asthma, gynecology and women's health, central nervous system, oncology, immunology, genomics, metabolic disorders, dermatology, urology, pediatrics, gastrointestinal, anti-infective, and nonsteroidal anti-inflammatory drug therapies, as well as engages in the bio clinical research activities. It operates through network consists of labs, LupiMitra collection centers, and pick-up points. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for LUPIN
Revenue projections for LUPIN

LUPIN's revenue is projected to decrease from last year, a development that could lead investors to adopt a more cautious approach. A revenue decline can negatively affect profitability, signaling challenges for the company and making it less attractive for those seeking solid financial performance.

Financial Ratios:

currentRatio 0.000000
forwardPE 20.870016
debtToEquity 31.500000
earningsGrowth 0.519000
revenueGrowth 0.133000
grossMargins 0.683230
operatingMargins 0.223940
trailingEps 71.600000
forwardEps 81.760000

LUPIN's Forward PE ratio is favorable, meaning the stock price aligns well with earnings and isn't overvalued. This allows room for growth, making it an attractive investment for those seeking potential upside while ensuring the stock is not overpriced.
With positive earnings and revenue growth, LUPIN is on a path to expand its business. This strong financial performance suggests the company will continue to grow, as increasing profits and revenue highlight a healthy outlook.
With positive gross and operating margins, LUPIN demonstrates strong profitability. This reflects the company's ability to manage costs and maintain healthy profits, showcasing effective operational efficiency and financial stability.
LUPIN's forward EPS being higher than its trailing EPS signals anticipated growth in profitability for the current financial year. This suggests that LUPIN is on track to improve its earnings, outpacing the previous year's performance and reflecting positive market expectations.

Price projections:

Price projections for LUPIN
Price projections for LUPIN

Price projections for Lupin Limited have steadily increased, reflecting growing optimism about the company's future. This trend suggests that analysts believe Lupin Limited is well-positioned for continued success.

Recommendation changes over time:

Recommendations trend for LUPIN
Recommendations trend for LUPIN


With analysts showing a buy bias for Lupin Limited, investors may be more inclined to see the stock as an attractive investment. The favorable outlook could spur increased interest, positioning Lupin Limited as a safe and profitable place for investors to allocate their funds and seek growth.